SCHEMBL5386370

SCHEMBL5386370

O=c1[nH]c2ccccc2n1C1CCN([C@H]2C[C@H]3CNC[C@H]3C2)CC1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 7/20 0.69
CHRM2 P08172 4/20 0.69
CHRM4 P08173 4/20 0.69
CHRM3 P20309 3/20 0.69
OPRM1 P35372 7/20 0.60
SLC18A3 Q16572 1/20 0.60
CHRM5 P08912 2/20 0.56
DRD2 P14416 2/20 0.56
ADRA1D P25100 1/20 0.56
HTR2C P28335 1/20 0.56
ADRA1A P35348 1/20 0.56
ADRA1B P35368 1/20 0.56
OPRK1 P41145 3/20 0.56
OPRL1 P41146 3/20 0.56
OPRD1 P41143 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5386373 1.00 CHRM1 (0.69) CHRM1CHRM2CHRM4CHRM3OPRM1
SCHEMBL6600748 1.00 CHRM1 (0.69) CHRM1CHRM2CHRM4CHRM3OPRM1
Hydrochloric Acid SCHEMBL5379970 0.99 CHRM1 (0.67) CHRM1CHRM2CHRM4CHRM3OPRM1
Hydrochloric Acid SCHEMBL5388919 0.99 CHRM1 (0.67) CHRM1CHRM2CHRM4CHRM3OPRM1
SCHEMBL5386489 0.90 CHRM1 (0.69) CHRM1CHRM2CHRM4CHRM3OPRM1
SCHEMBL6579859 0.90 CHRM1 (0.76) CHRM1CHRM2CHRM4CHRM3OPRM1
SCHEMBL4403937 0.84 CHRM1 (0.70) CHRM1CHRM2CHRM4CHRM3OPRM1
SCHEMBL3710702 0.83 CHRM1 (0.78) CHRM1CHRM2CHRM4CHRM3OPRM1
SCHEMBL3895786 0.83 CHRM1 (0.92) CHRM1CHRM2CHRM4CHRM3OPRM1
SCHEMBL4748900 0.82 CHRM1 (0.70) CHRM1CHRM2CHRM4CHRM3OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7164024-B2 Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-16 US disclosed
US-20040147506-A1 Benzimidazolone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-07-29 US disclosed
EP-1386920-A1 BENZIMIDAZOLONE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147506-A1 Benzimidazolone derivatives HRH2, CCKAR, HRH4 CHRM1 4/4885CHRM2 10/4885CHRM4 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.